MX2013012344A - Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. - Google Patents

Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.

Info

Publication number
MX2013012344A
MX2013012344A MX2013012344A MX2013012344A MX2013012344A MX 2013012344 A MX2013012344 A MX 2013012344A MX 2013012344 A MX2013012344 A MX 2013012344A MX 2013012344 A MX2013012344 A MX 2013012344A MX 2013012344 A MX2013012344 A MX 2013012344A
Authority
MX
Mexico
Prior art keywords
difficile toxin
clostridium difficile
mutant
methods
relates
Prior art date
Application number
MX2013012344A
Other languages
English (en)
Other versions
MX347521B (es
Inventor
Kathrin Ute Jansen
Mark E Ruppen
Annaliesa Sybil Anderson
Maninder K Sidhu
Robert G K Donald
Narender K Kalyan
Terri L Mininni
Justin Keith Moran
Michael James Flint
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2013012344A publication Critical patent/MX2013012344A/es
Publication of MX347521B publication Critical patent/MX347521B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En un aspecto, la invención se refiere a una composición inmunogénica que incluye una toxina A de Clostridium difficile mutante y/o una toxina B de Clostridium difficile mutante; cada toxina mutante incluye un dominio de glucosiltransferasa que tiene al menos una mutación y un dominio de cisteína proteasa que tiene al menos una mutación, con respecto a la correspondiente toxina de C. difficile tipo salvaje; las toxinas mutantes también pueden incluir al menos un aminoácido que está entrecruzado químicamente; en otro aspecto, la invención se refiere a anticuerpos o fragmentos de unión a este que se unen a dichas composiciones inmunogénicas; en un aspecto adicional, la invención se refiere a secuencias de nucleótidos aisladas que codifican alguna de los precedentes y los métodos de cualquiera de las composiciones precedentes.
MX2013012344A 2011-04-22 2012-04-20 Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. MX347521B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US201161478899P 2011-04-25 2011-04-25
PCT/IB2012/051999 WO2012143902A1 (en) 2011-04-22 2012-04-20 Compositions relating to a mutant clostridium difficile toxin and methods thereof

Publications (2)

Publication Number Publication Date
MX2013012344A true MX2013012344A (es) 2013-11-20
MX347521B MX347521B (es) 2017-04-27

Family

ID=46085103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012344A MX347521B (es) 2011-04-22 2012-04-20 Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.

Country Status (29)

Country Link
US (13) US8481692B2 (es)
EP (4) EP3549949B1 (es)
JP (8) JP5917682B2 (es)
KR (1) KR101667837B1 (es)
CN (3) CN107022532B (es)
AR (1) AR086199A1 (es)
AU (6) AU2012245904B2 (es)
BR (2) BR112013027229B1 (es)
CA (1) CA2832712C (es)
CO (1) CO6801643A2 (es)
DK (2) DK3549949T3 (es)
ES (3) ES2742823T3 (es)
FI (1) FI3549949T3 (es)
HR (2) HRP20240042T1 (es)
HU (1) HUE047085T2 (es)
IL (8) IL270779B1 (es)
MX (1) MX347521B (es)
MY (2) MY182429A (es)
NZ (1) NZ616035A (es)
PE (2) PE20141029A1 (es)
PL (3) PL3505531T3 (es)
PT (2) PT2699587T (es)
RU (2) RU2754446C2 (es)
SA (3) SA115360697B1 (es)
SG (3) SG10201602668VA (es)
SI (3) SI3505531T1 (es)
TW (6) TWI686402B (es)
WO (1) WO2012143902A1 (es)
ZA (1) ZA201307818B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2507553T3 (es) * 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
HUE027823T2 (hu) * 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
SI2753352T2 (sl) 2010-09-03 2022-10-28 Valneva Austria Gmbh Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
NZ616035A (en) * 2011-04-22 2016-03-31 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
DK2888283T3 (en) 2012-08-24 2018-11-19 Univ California ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
ES2676468T3 (es) * 2012-11-06 2018-07-19 Bayer Pharma Aktiengesellschaft Formulación de acopladores biespecíficos de linfocitos T (BiTE)
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
US10226523B2 (en) * 2013-04-22 2019-03-12 The Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
CA2954087C (en) * 2014-07-25 2023-09-19 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
WO2016130923A1 (en) * 2015-02-13 2016-08-18 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
CA3076961A1 (en) * 2017-09-28 2019-04-04 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2020201985A1 (en) * 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
US20220313809A1 (en) * 2019-05-10 2022-10-06 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile tcdb variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
WO2021226330A1 (en) * 2020-05-06 2021-11-11 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
WO2023175454A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. Methods for producing an adjuvant
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
DE69223955T2 (de) 1991-04-22 1998-08-13 Massachusetts Health Res Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
ES2199227T5 (es) 1993-03-29 2007-12-01 Pfizer Inc. Vacunas clostridiales multicomponente que usan adyuvantes de saponina.
MX9701683A (es) 1994-09-06 1997-06-28 Galagen Inc Tratamiento terapeutico de enfermedades asociadas a clostridium difficile.
NZ337543A (en) 1994-10-24 2002-06-28 Allergan Inc Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
CN1195297A (zh) 1995-07-07 1998-10-07 奥拉瓦克斯有限公司 艰难梭菌毒素作为粘膜佐剂
EP0877623A1 (en) 1995-07-07 1998-11-18 Oravax, Inc. Intranasal vaccination against gastrointestinal disease
EP0952773B1 (en) 1995-09-15 2005-11-23 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
CN1230266A (zh) 1996-07-12 1999-09-29 埃德温·C·伊利夫 带网络存取的计算机化医疗诊断及治疗咨询系统
IL128014A (en) 1996-09-30 2003-11-23 Univ Arkansas Method of producing active immunity with vaccine conjugate, a vaccine preparation useful for the production of said vaccine conjugate and a process for the manufacture of said vaccine
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
CA2365915C (en) 1999-04-09 2015-11-24 Techlab, Inc. Recombinant toxin a/toxin b vaccine against clostridium difficile
CA2365914A1 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
HU229255B1 (en) 1999-04-19 2013-10-28 Smithkline Beecham Biolog Vaccines
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
US7037503B2 (en) * 2000-05-04 2006-05-02 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
CA2450783A1 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
EP1514928B1 (en) 2002-06-05 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Method for producing antibodies using baculoviruses
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
RU2340627C2 (ru) * 2003-03-13 2008-12-10 ГлаксоСмитКлайн Байолоджикалз с.а. Способ очистки бактериального цитолизина
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
BRPI0506917A (pt) 2004-01-16 2007-06-05 Dow Global Technologies Inc expressão de proteìnas de mamìferos em pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
US7625559B2 (en) 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
AU2005321974B2 (en) * 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
EP1987361A4 (en) * 2006-01-30 2009-03-04 Invitrogen Corp COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES
KR101149687B1 (ko) * 2006-03-30 2012-05-25 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US8554548B2 (en) * 2007-03-02 2013-10-08 Panasonic Corporation Speech decoding apparatus and speech decoding method including high band emphasis processing
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US8206940B2 (en) 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
CA2729248A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
CA2733425A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
CA2738248A1 (en) 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for clostridium difficile toxin production
WO2010040000A2 (en) 2008-10-01 2010-04-08 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services A multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
RU2011126602A (ru) 2008-12-03 2013-01-10 Берингер Ингельхайм Ветмедика Гмбх Способ получения вакцин
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
AU2010215275B2 (en) * 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
AU2011238711B2 (en) 2010-03-30 2015-06-18 Pelican Technology Holdings, Inc. High level expression of recombinant toxin proteins
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
SI2753352T2 (sl) 2010-09-03 2022-10-28 Valneva Austria Gmbh Izoliran polipeptid proteinov toksina a in toksina b c. difficile in njegova uporaba
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012078313A2 (en) * 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
NZ616035A (en) 2011-04-22 2016-03-31 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
SI2714911T1 (sl) 2011-05-27 2017-03-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP2897637A1 (en) 2012-09-19 2015-07-29 Novartis AG Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2925362A4 (en) 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
SI2928489T1 (sl) 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni sestavek
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CA2907154A1 (en) 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxoids, compositions and related methods
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
US20160250283A1 (en) 2013-10-23 2016-09-01 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3377613A1 (en) 2015-11-17 2018-09-26 Pfizer Inc Media and fermentation methods for producing polysaccharides in bacterial cell culture
CN117244049A (zh) 2016-02-16 2023-12-19 哈佛学院院长等 病原体疫苗及其生产和使用方法
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
CA3076961A1 (en) 2017-09-28 2019-04-04 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
AU2016202903B2 (en) 2017-11-30
WO2012143902A1 (en) 2012-10-26
SA112330472B1 (ar) 2015-11-02
SI2699587T1 (sl) 2019-08-30
JP7097478B2 (ja) 2022-07-07
TW201806967A (zh) 2018-03-01
CO6801643A2 (es) 2013-11-29
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
NZ616035A (en) 2016-03-31
JP2021130692A (ja) 2021-09-09
AU2012245904A1 (en) 2013-10-17
RU2592686C2 (ru) 2016-07-27
AU2019246878B2 (en) 2020-09-10
TW202320843A (zh) 2023-06-01
PT2699587T (pt) 2019-09-05
EP3505531B1 (en) 2023-11-15
RU2754446C2 (ru) 2021-09-02
AU2017261465B2 (en) 2018-10-04
AU2018201296A1 (en) 2018-03-15
TW201302780A (zh) 2013-01-16
JP6892425B2 (ja) 2021-06-23
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
IL265510B (en) 2021-05-31
US10774117B2 (en) 2020-09-15
EP2699587A1 (en) 2014-02-26
US20230391835A1 (en) 2023-12-07
CN111647059B (zh) 2023-11-28
EP3549949A1 (en) 2019-10-09
HUE047085T2 (hu) 2020-04-28
AU2016202903A1 (en) 2016-05-26
MX347521B (es) 2017-04-27
DK3549949T3 (da) 2023-12-18
JP2014514318A (ja) 2014-06-19
ZA201307818B (en) 2014-06-25
JP5917682B2 (ja) 2016-05-18
TWI650329B (zh) 2019-02-11
PL3505531T3 (pl) 2024-03-11
HRP20240042T1 (hr) 2024-03-29
US20200095290A1 (en) 2020-03-26
JP2016117745A (ja) 2016-06-30
JP2019052149A (ja) 2019-04-04
US20190202873A1 (en) 2019-07-04
IL245047A0 (en) 2016-05-31
TWI804717B (zh) 2023-06-11
JP2017125030A (ja) 2017-07-20
TW201932481A (zh) 2019-08-16
IL228944A (en) 2017-11-30
EP4365196A2 (en) 2024-05-08
US20130244307A1 (en) 2013-09-19
EP3549949B1 (en) 2023-11-29
AU2020230248B2 (en) 2022-12-01
JP6321239B2 (ja) 2018-05-09
TW202041525A (zh) 2020-11-16
TWI701257B (zh) 2020-08-11
IL254440B (en) 2019-12-31
IL265510A (en) 2019-05-30
TW201932480A (zh) 2019-08-16
US11535652B2 (en) 2022-12-27
AU2012245904B2 (en) 2016-04-21
PE20141029A1 (es) 2014-09-04
AR086199A1 (es) 2013-11-27
US20120269841A1 (en) 2012-10-25
US8900597B2 (en) 2014-12-02
CN103619871A (zh) 2014-03-05
SI3505531T1 (sl) 2024-02-29
SG194132A1 (en) 2013-11-29
ES2968629T3 (es) 2024-05-13
BR112013027229A2 (pt) 2016-11-29
IL273231B (en) 2021-08-31
PL2699587T3 (pl) 2019-12-31
US20150307563A1 (en) 2015-10-29
JP2018052938A (ja) 2018-04-05
IL273231A (en) 2020-04-30
US9745354B2 (en) 2017-08-29
JP2018135345A (ja) 2018-08-30
SA115360698B1 (ar) 2016-04-27
RU2013145170A (ru) 2015-06-27
JP2022126822A (ja) 2022-08-30
IL255345B (en) 2021-05-31
IL255345A0 (en) 2017-12-31
CN107022532B (zh) 2021-05-04
PT3549949T (pt) 2024-02-02
AU2019246878A1 (en) 2019-10-31
EP3505531A1 (en) 2019-07-03
JP6735784B2 (ja) 2020-08-05
AU2020230248A1 (en) 2020-10-01
IL254418B (en) 2019-12-31
RU2015154443A (ru) 2019-01-17
HRP20231631T1 (hr) 2024-03-15
PL3549949T3 (pl) 2024-04-08
JP6097853B2 (ja) 2017-03-15
IL254418A0 (en) 2017-11-30
IL270779A (en) 2020-01-30
BR122019017005B1 (pt) 2022-03-29
RU2015154443A3 (es) 2019-05-22
FI3549949T3 (fi) 2024-01-30
TWI815599B (zh) 2023-09-11
USRE46518E1 (en) 2017-08-22
DK2699587T3 (da) 2019-08-05
CN107022532A (zh) 2017-08-08
MY168205A (en) 2018-10-15
TWI671313B (zh) 2019-09-11
SG10201602668VA (en) 2016-05-30
USRE48863E1 (en) 2021-12-28
PE20181334A1 (es) 2018-08-21
AU2017261465A1 (en) 2017-11-30
ES2742823T3 (es) 2020-02-17
KR101667837B1 (ko) 2016-10-20
EP2699587B1 (en) 2019-07-03
CN103619871B (zh) 2016-12-14
CA2832712C (en) 2018-08-28
US9187536B1 (en) 2015-11-17
SG10201911993UA (en) 2020-02-27
US20130330371A1 (en) 2013-12-12
USRE48862E1 (en) 2021-12-28
MY182429A (en) 2021-01-25
US20150125927A1 (en) 2015-05-07
US10597428B2 (en) 2020-03-24
US8481692B2 (en) 2013-07-09
CN111647059A (zh) 2020-09-11
ES2969952T3 (es) 2024-05-23
SA115360697B1 (ar) 2016-04-05
IL228944A0 (en) 2013-12-31
US20170313749A1 (en) 2017-11-02
US8557548B2 (en) 2013-10-15
BR112013027229B1 (pt) 2020-10-27
CA2832712A1 (en) 2012-10-26
USRE46376E1 (en) 2017-04-25
KR20130140206A (ko) 2013-12-23

Similar Documents

Publication Publication Date Title
MY182429A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
MX2019013075A (es) Composiciones y metodos relacionados con una toxina mutante de clostridium difficile.
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
WO2012096926A3 (en) Method for delivering agents into cells using bacterial toxins
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EP4296361A3 (en) Immunogenic composition
WO2009149200A3 (en) Compositions and methods comprising variant microbial proteases
WO2010129304A3 (en) Method for making heteromultimeric molecules
MY156315A (en) Anti-vegf antibodies
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EP3892709A3 (en) Variants and compositions comprising variants with high stability in presence of a chelating agent
MX350126B (es) Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
IN2014MN01868A (es)
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
BR112015014727A2 (pt) composição imunogênica, uso de uma composição imunogênica, e, método para prevenir ou tratar a doença c.difficile
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
MX2016008989A (es) Fragmentos mutantes de ospa y metodos y usos relacionados con estos.
AU2017329645A8 (en) Novel antibodies against Factor XI and uses thereof
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
WO2012142113A3 (en) Isopeptide bond formation in bacillus species and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration